LU92509I2 - Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) - Google Patents

Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) Download PDF

Info

Publication number
LU92509I2
LU92509I2 LU92509C LU92509C LU92509I2 LU 92509 I2 LU92509 I2 LU 92509I2 LU 92509 C LU92509 C LU 92509C LU 92509 C LU92509 C LU 92509C LU 92509 I2 LU92509 I2 LU 92509I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
travatan
travoprost
acceptable derivatives
disclosed
Prior art date
Application number
LU92509C
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92509(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of LU92509I2 publication Critical patent/LU92509I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
LU92509C 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) LU92509I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/101,598 US5510383A (en) 1993-08-03 1993-08-03 Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
LU92509I2 true LU92509I2 (fr) 2015-10-21

Family

ID=22285486

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
LU92509C LU92509I2 (fr) 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)

Country Status (12)

Country Link
US (3) US5510383A (fr)
EP (3) EP0639563B2 (fr)
JP (2) JP2791544B2 (fr)
AT (1) ATE286880T2 (fr)
AU (2) AU690120B2 (fr)
CA (1) CA2129287C (fr)
DE (1) DE69434228T2 (fr)
DK (3) DK1920764T4 (fr)
ES (3) ES2235158T5 (fr)
LU (2) LU92058I2 (fr)
PT (3) PT1920764E (fr)
SI (3) SI1514548T1 (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
WO1997023225A1 (fr) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinaisons de prostaglandines de type dp et fp destinees a abaisser la pression intraoculaire
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
WO1998019680A1 (fr) * 1996-11-01 1998-05-14 Alcon Laboratories, Inc. Utilisation d'une combinaison d'inhibiteurs d'anhydrase carbonique et de prostaglandines dans le traitement du glaucome
DE69705421T2 (de) 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
IL134839A0 (en) * 1997-09-09 2001-05-20 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
DK1012137T3 (da) * 1997-09-09 2003-03-10 Procter & Gamble Aromatiske C-16-C-20-substituerede tetrahydro-prostaglandiner og deres anvendelse som prostaglandin FP-agonister
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
WO2000051980A1 (fr) 1999-03-05 2000-09-08 The Procter & Gamble Company Analogues de prostaglandines c16 fp selectives insaturees
US6294679B1 (en) * 1999-04-12 2001-09-25 Chirotech Technology Limited Intermediate for the synthesis of prostaglandins
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
GB9908326D0 (en) * 1999-04-12 1999-06-09 Chirotech Technology Ltd Novel process intermediate for the synthesis of prostaglandins
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
JP2003531824A (ja) * 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー，インク． フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004098807A1 (fr) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Procede de fabrication de coupleurs en acier permettant d'assembler des barres d'armature du beton
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20050171054A1 (en) * 2001-01-19 2005-08-04 Helge Rask-Andersen Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss
WO2002085248A2 (fr) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoides pouvant augmenter la penetration de medicaments oculaires
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
GB0112699D0 (en) * 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
DK1392292T3 (da) * 2001-06-01 2006-05-29 Alcon Inc Pyranoindazoler og deres anvendelse til behandling af glaukom
WO2002098860A1 (fr) * 2001-06-01 2002-12-12 Alcon, Inc. Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
MXPA03010806A (es) * 2001-06-01 2004-11-22 Alcon Inc Nuevos analogos de arilaminopropano y su uso para el tratamiento de glaucoma.
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
WO2003079997A2 (fr) * 2002-03-21 2003-10-02 Cayman Chemical Company Analogues de la prostaglandine f2? et leur utilisation combinee a des proteines antimicrobiennes dans le traitement du glaucome et de l'hypertension intra-oculaire
DE60334905D1 (de) 2002-06-06 2010-12-23 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
WO2004019938A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
PL375564A1 (en) * 2002-08-30 2005-11-28 Alcon, Inc. Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (fr) * 2002-11-08 2007-07-25 Merck & Co Inc Compositions ophtalmiques pour traiter l'hypertension oculaire
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20070088045A1 (en) * 2002-11-12 2007-04-19 Hellberg Peggy E Histone deacetylase inhibitors for treating degenerative diseases of the eye
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
WO2004054572A2 (fr) * 2002-12-13 2004-07-01 Alcon, Inc. Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
US20060148805A1 (en) * 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
EP1664011A4 (fr) * 2003-09-02 2009-02-25 Merck & Co Inc Compositions ophtalmiques pour le traitement de l'hypertension oculaire
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
WO2005025568A1 (fr) * 2003-09-04 2005-03-24 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
MXPA06002484A (es) * 2003-09-05 2006-06-20 Novartis Ag Composiciones que comprenden derivados de benzo[g]quinolina y derivados de prostaglandina.
DE602004023106D1 (de) 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US6989445B2 (en) * 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (fr) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Gouttes pour les yeux transparentes au latanoprost
DE602005008935D1 (de) * 2004-04-26 2008-09-25 Alcon Inc Statine zur behandlung von okularer hypertonie und glaukom
CA2574078A1 (fr) 2004-07-20 2006-02-23 Merck & Co., Inc. Compositions ophtalmiques traitant l'hypertension oculaire
US20080097108A1 (en) * 2004-10-13 2008-04-24 Ying-Duo Gao Ophthalmic Compositions for Treating Ocular Hypertension
JP2008515982A (ja) * 2004-10-13 2008-05-15 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科組成物
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
WO2006062839A1 (fr) * 2004-12-08 2006-06-15 Alcon, Inc. Utilisation de dioxindoindazoles et de dioxoloindazoles pour traiter le glaucome
BRPI0605926A2 (pt) * 2005-01-14 2009-05-26 Allergan Inc ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
SI1864666T1 (sl) 2005-03-31 2012-10-30 Asahi Glass Co Ltd Zaščitno sredstvo za retinalno nevronsko celico, vsebujoče derivat prostaglandina F2 alfa kot učinkovino
WO2006112313A1 (fr) 2005-04-13 2006-10-26 Ube Industries, Ltd. Agent protecteur pour une cellule neuronale retinienne comprenant un derive d’indazole comme ingredient actif
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
AU2006275263A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1810967B1 (fr) 2006-01-18 2014-07-30 Chirogate International Inc. Procédé et produits intérmediaires pour la fabrication de prostaglandines
US20070219272A1 (en) * 2006-02-06 2007-09-20 Johan Stjernschantz Novel method and compositions for treatment of tinnitus
CA2644716A1 (fr) * 2006-03-13 2007-09-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
WO2007111806A2 (fr) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Compositions et procedes pour la reduction des tissus adipeux de l'organisme
AU2007258527A1 (en) * 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
CN101622243B (zh) 2007-02-28 2013-12-04 旭化成制药株式会社 磺酰胺衍生物
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
EP2291346A2 (fr) * 2008-05-15 2011-03-09 Allergan, Inc. Cyclopentanes substitués à visée thérapeutique
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2349242B1 (fr) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Sels d'acides aminés de prostaglandines
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010112615A1 (fr) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Dérivés de lysine fonctionnalisés avec des lipides
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
RU2012115103A (ru) 2009-09-17 2013-10-27 Сэндзю Фармасьютикал Ко., Лтд. Водные глазные капли, содержащие латанопрост, и способ ингибирования адсорбции латанопроста полимером
NZ628266A (en) * 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2600825B1 (fr) 2010-08-02 2018-12-12 Ac Patent Holding Inc. Procédé pour le bouclage de cheveux
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
EP3378480A1 (fr) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Procédés et compositions de traitement du syndrome métabolique
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
WO2013133730A1 (fr) * 2012-03-09 2013-09-12 Instytut Farmaceutyczny Procédé de préparation d'analogues de prostaglandine f2α
CN104936595A (zh) 2012-11-21 2015-09-23 托普凯恩制药公司 局部增加体脂肪的方法和组合物
HU230744B1 (hu) 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
EP2976080B1 (fr) 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Conjugés de composés isoquinoline et de prostaglandines
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
HU231214B1 (hu) 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CN112022856A (zh) * 2014-10-15 2020-12-04 爱尔康公司 用于治疗青光眼和眼压过高的前列腺素偶联物和衍生物
WO2016063184A1 (fr) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Solution ophtalmique
JP6686023B2 (ja) 2014-11-25 2020-04-22 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法
WO2016155906A1 (fr) 2015-03-31 2016-10-06 Nicox S.A. Dérivés de fluprosténol donneurs d'oxyde nitrique
CA2999988C (fr) 2015-09-27 2024-06-11 Follica, Inc. Dispositif de piqure et applicateur de medicament
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
GB1350971A (en) * 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
GB1486832A (en) * 1974-08-05 1977-09-28 Ici Ltd Prostanoic acid derivatives
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4159343A (en) * 1975-05-26 1979-06-26 Schering Aktiengesellschaft Prostane derivatives
DE2523676A1 (de) * 1975-05-26 1976-12-16 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
ATE111736T1 (de) * 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
HU212570B (en) † 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP0664707B1 (fr) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
LU92058I2 (fr) 2012-10-08
EP1920764B1 (fr) 2012-05-16
DK1920764T4 (da) 2020-03-16
AU7748898A (en) 1998-10-01
PT1514548E (pt) 2014-04-22
EP0639563A3 (fr) 1996-10-16
DK1920764T3 (da) 2012-07-02
EP0639563A2 (fr) 1995-02-22
US5510383A (en) 1996-04-23
JP2791544B2 (ja) 1998-08-27
JPH07165703A (ja) 1995-06-27
PT639563E (pt) 2005-05-31
EP0639563B2 (fr) 2015-09-30
SI1920764T1 (sl) 2012-08-31
CA2129287A1 (fr) 1995-02-04
EP1514548B1 (fr) 2014-02-26
SI0639563T1 (en) 2005-06-30
ES2458493T3 (es) 2014-05-05
ES2235158T3 (es) 2005-07-01
AU690120B2 (en) 1998-04-23
HK1072716A1 (en) 2005-09-09
PT1920764E (pt) 2012-07-20
ES2235158T5 (es) 2016-05-25
HK1010717A1 (en) 1999-06-25
SI1920764T2 (sl) 2020-03-31
ATE286880T2 (de) 2005-01-15
JPH10182465A (ja) 1998-07-07
AU6877994A (en) 1995-02-23
CA2129287C (fr) 2002-05-14
DE69434228T2 (de) 2006-02-02
DK0639563T4 (en) 2016-01-11
SI1514548T1 (sl) 2014-04-30
DK0639563T3 (da) 2005-03-21
JP3650258B2 (ja) 2005-05-18
DK1514548T3 (da) 2014-03-17
EP1514548A2 (fr) 2005-03-16
ES2385267T5 (es) 2020-07-21
AU704670B2 (en) 1999-04-29
US5889052A (en) 1999-03-30
ES2458493T8 (es) 2014-08-27
EP1514548A3 (fr) 2005-04-06
DE69434228D1 (de) 2005-02-17
EP1920764A1 (fr) 2008-05-14
ES2385267T3 (es) 2012-07-20
EP0639563B1 (fr) 2005-01-12
EP1920764B2 (fr) 2020-01-08
US5665773A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
LU92509I2 (fr) Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
RU95110762A (ru) Производные 5-гидразинохинолона, композиция для лечения или профилактики инфекционного заболевания, способ лечения или профилактики
ATE326972T1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
EP0667160A3 (fr) Utilisation d'analogues de prostaglandines pour le traitement de hypertension oculaire et le glaucome.
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
NO973122D0 (no) Middel for å minske okular spenning
ATE289817T1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
NO20020475D0 (no) 2-aminotetralinderivater for terapi av glaukom
EP1300149A3 (fr) Dérivés de prostaglandines servant au traitement du glaucome ou de l'hypertension oculaire